None of the anti-cancer drug loaded-RBC-technology has reached the market till now, however, few clinical trials on RBC-based technology have been conducted for dexamethasone-21-phosphate in ataxia telangiectasia, asparaginase in pancreatic cancer, lymphoblastic leukemia, thymidine phosphorylase in mitochondrial neuro-gastrointestinal encephalomyopathy and RTX-134 in phenylketonuria, etc., as reported [112]. The gene discussed is ASPG; the disease is acute lymphoblastic leukemia.